GU Cancer Clinical Trials

DISCLAIMER: All content found on cua.org is provided for information and education purposes. The medical information and clinical trials information is not intended to substitute for the advice of a physician, nor is it intended to provide legal advice. You should always consult your doctor for specific information on personal health matters, or other relevant professionals to ensure that your own circumstances are considered.

The CUA is not responsible in any manner for direct, indirect, special or consequential damages caused and/or arising from your use of cua.org.

Subspecialty
Bladder | AB, QC | Active, not recruiting
CheckMate 274
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
Start Date: March 22, 2016

NCT #: NCT02632409

SPONSOR: BMS

INFO:  https://clinicaltrials.gov/ct2/show/NCT02632409?term=checkmate+274&draw=2&rank=1

CONTACT: Bristol-Myers Squibb in Collaboration with Ono Pharmaceutical Co. Ltd.

OTHER CANADIAN CENTRES:

1. Cross Cancer Institute (Edmonton, AB)

2. McGill University Health Centre (Montreal, QC)

3. Hopital Fleurimont (CHUS) (Sherbrook, QC)

4. Centre Hospitalier De L'Universite De Montreal (Montreal, QC)

 

Bladder | AB, BC, MB, NS, ON, QC | Recruiting
CBCIS
Canadian Bladder Cancer Information System
Dr. Wassim Kassouf & Dr. Peter Black (Co-Chairs)
Start Date: January 1, 2015

SPONSOR: Bladder Cancer Canada

INFO: https://bladdercancercanada.org/en/canadian-bladder-cancer-information-system/

CONTACT: camilla.tajzler@muhc.mcgill.ca

OTHER CANADIAN CENTRES:
1. McGill University Health Centre (Montreal): Dr. W. Kassouf                                                                          
2. Univesity of British Columbia (Vancouver): Dr. P. Black                                               
3. Cross Cancer Centre (Edmonton): Dr. A. Fairey                                                            
4. Alberta Health Services (Calgary): Dr. E. Hyndman                                                       
5. Manitoba CancerCare (Winnipeg): Dr. J. Graham                                                        
6. Western University (Longon): Dr. J. Izawa                                                                       
7. McMaster University (Hamilton): Dr. B. Shayegan                                                      
8. University Health Network (Toronto): Dr. G. Kulkarni                                                     
9. Ottawa Hospital: Dr. R. Breau                                                                                           
10. Centre hospitalier d’université de Montréal (CHUM) (Montreal): Dr. JB. Lattouf                     
11. Centre hospitalier d'université du Québec (CHUQ) (Québec): Dr. M. Lodde               
12. Capital Health (Halifax): Dr. R. Rendon                                                                            
13. Kingston General Hospital (Kingston): Dr. R. Siemens                                                   
14. Université de Sherbrooke (Sherbrooke): Dr. C. Jeldres

Renal | AB, BC, MB, NS, ON, QC | Recruiting
CKCis
Canadian Kidney Cancer information system
Dr. Rodney Breau & Dr. Naveen Basappa (Co-Chairs)
Start Date: January 1, 2011

SPONSOR: KCRNC

INFO: https://www.kcrnc.ca/ckcis/

CONTACT:  CT.Solutions@pm.me

Prostate | ON, QC | Active, not recruiting
RADICALS
Radiotherapy and Androgen Deprivation In Combination After Local Surgery
Start Date: October 31, 2006
Renal | ON | Recruiting
AREN03B2
Study of Kidney Tumors in Younger Patients
Children's Oncology Group in Collaboration with National Cancer Institute (NCI)
Start Date: February 27, 2006

NCT #:  NCT00898365

SPONSOR: Children's Oncology Group in Collaboration with National Cancer Institute (NCI)

INFO: https://clinicaltrials.gov/ct2/show/NCT00898365?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=21

CONTACT: 

Kingston Health Sciences Centre (Kingston): 613-549-6666                      

Children's Hospital of Eastern Ontario (Ottawa): 613-738-3931

OTHER CANADIAN CENTRES: 

Kingston & Ottawa

 

Prostate | AB | Planned
PR25
A Phase III Trial Investigating Platinum and Taxane Chemotherapy in Metastatic Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes
Dr. Michael Kolinsky (Cross Cancer Institute)

CONTACT:

780-432-8762

Prostate | ON, QC | Planned
PR23
A Randomized Phase II Trial Evaluating the Impact of SBRT with or without Nirapariib in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with ADT and Androgen Axis Directed Therapy
Dr. M. Tamim Niazi (JGH) & Dr. Sebastien Hotte (JCC)

CONTACT:

(514) 340-8288

(905) 387-9495 Ext. 64605

Bladder | ON | Recruiting
BL13F
Electronic 'Real-Time' Patient Self-Reporting of Immunotherapy Symptomatic Adverse Events using the SYMPTOM-IQ Tool on the uMotif Mobile Health Application (APP): A Prospective Feasibility Sub-Study of BL13 [e-PRISM]
Dr. Doris Howell (UHN)

CONTACT: (416) 946-4501 Ext. 3419

Renal | ON, QC | Recruiting
NCI-2014-01984
Study of PF-07265807 in Participants With Metastatic Solid Tumors
Pfizer

NCT #: NCT04458259

SPONSOR: Pfizer

INFO: https://clinicaltrials.gov/ct2/show/NCT04458259?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=32

CONTACT: ClinicalTrials.gov_Inquiries@pfizer.com

OTHER CANADIAN CENTRES:

Juravinski Cancer Centre (Hamilton)                                                    

University Health Network (Toronto)                                                          

CHU de Quebec Universite Laval (Quebec City)

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy